Incannex Healthcare is planning to redomicile to the US in a move designed to access deeper pools of capital and increase the company’s long-term market valuation.

A newly formed company will become Incannex’s (IXHL) parent and issue shares on Nasdaq, in exchange for all Incannex’s existing common shares. The biotech company, which is currently dual-listed and based in Australia, will continue to focus on developing medicinal cannabis and psychedelic therapies.

In this interview, CEO Joel Latham discusses topics including:

• How the redomiciling and Nasdaq listing will impact active clinical programmes;
• What it will mean for future clinical development programmes;
• How the move will affect operational strategy; and
• The implications for the current shareholders.

More By This Author: